Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

Approximately 4% of NSCLC harbor BRAF mutations, and approximately 50% of these are non-V600 mutations. Treatment of tumors harboring non-V600 mutations is challenging because of functional heterogeneity and lack of knowledge regarding their clinical significance and response to targeted agents. We...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of thoracic oncology 2020-10, Vol.15 (10), p.1611-1623
Hauptverfasser:	Negrao, Marcelo V., Raymond, Victoria M., Lanman, Richard B., Robichaux, Jacqulyne P., He, Junqin, Nilsson, Monique B., Ng, Patrick K.S., Amador, Bianca E., Roarty, Emily B., Nagy, Rebecca J., Banks, Kimberly C., Zhu, Viola W., Ng, Chun, Chae, Young Kwang, Clarke, Jeffrey M., Crawford, Jeffrey A., Meric-Bernstam, Funda, Ignatius Ou, Sai-Hong, Gandara, David R., Heymach, John V., Bivona, Trever G., McCoach, Caroline E.
Format:	Artikel
Sprache:	eng
Schlagworte:	BRAF Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cell-free DNA Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Non–small cell lung cancer Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins B-raf - genetics Targeted therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!